ID   TAU_HUMAN               Reviewed;         758 AA.
AC   P10636; P18518; Q14799; Q15549; Q15550; Q15551; Q1RMF6; Q53YB1;
AC   Q5CZI7; Q5XWF0; Q6QT54; Q9UDJ3; Q9UMH0; Q9UQ96;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   31-MAY-2011, sequence version 5.
DT   14-OCT-2015, entry version 218.
DE   RecName: Full=Microtubule-associated protein tau;
DE   AltName: Full=Neurofibrillary tangle protein;
DE   AltName: Full=Paired helical filament-tau;
DE            Short=PHF-tau;
GN   Name=MAPT; Synonyms=MAPTL, MTBT1, TAU;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM FETAL-TAU).
RC   TISSUE=Brain;
RX   PubMed=3131773; DOI=10.1073/pnas.85.11.4051;
RA   Goedert M., Wischik C., Crowther R., Walker J., Klug A.;
RT   "Cloning and sequencing of the cDNA encoding a core protein of the
RT   paired helical filament of Alzheimer disease: identification as the
RT   microtubule-associated protein tau.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:4051-4055(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TAU-D).
RC   TISSUE=Brain;
RX   PubMed=2498079;
RA   Goedert M., Spillantini M.G., Potier M.-C., Ulrich J., Crowther R.A.;
RT   "Cloning and sequencing of the cDNA encoding an isoform of
RT   microtubule-associated protein tau containing four tandem repeats:
RT   differential expression of tau protein mRNAs in human brain.";
RL   EMBO J. 8:393-399(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TAU-A AND FETAL-TAU).
RC   TISSUE=Fetal brain;
RX   PubMed=2516729; DOI=10.1016/0896-6273(89)90050-0;
RA   Lee G., Neve R.L., Kosik K.S.;
RT   "The microtubule binding domain of tau protein.";
RL   Neuron 2:1615-1624(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TAU-B; TAU-C; TAU-E AND TAU-F),
RP   AND ASSOCIATION WITH ALZHEIMER DISEASE.
RC   TISSUE=Brain;
RX   PubMed=2484340; DOI=10.1016/0896-6273(89)90210-9;
RA   Goedert M., Spillantini M.G., Jakes R., Rutherford D., Crowther R.A.;
RT   "Multiple isoforms of human microtubule-associated protein tau:
RT   sequences and localization in neurofibrillary tangles of Alzheimer's
RT   disease.";
RL   Neuron 3:519-526(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS PNS-TAU; FETAL-TAU AND
RP   TAU-F), ALTERNATIVE SPLICING, AND VARIANT HIS-441.
RX   PubMed=1420178; DOI=10.1021/bi00158a027;
RA   Andreadis A., Brown W.M., Kosik K.S.;
RT   "Structure and novel exons of the human tau gene.";
RL   Biochemistry 31:10626-10633(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TAU-E).
RA   Chun J., Kwon T., Lee E.-J., Hyun S.-H., Kang S.S.;
RT   "Cloning of tau-related genes.";
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM FETAL-TAU).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS FETAL-TAU AND TAU-D).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 2-73; 103-381; 468-497; 508-571; 577-583; 592-607;
RP   616-634; 639-657; 661-664; 671-700 AND 703-758, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT ALA-2, AND DEAMIDATION AT ASN-484.
RC   TISSUE=Brain;
RX   PubMed=1512244;
RA   Hasegawa M., Morishima-Kawashima M., Takio K., Suzuki M., Titani K.,
RA   Ihara Y.;
RT   "Protein sequence and mass spectrometric analyses of tau in the
RT   Alzheimer's disease brain.";
RL   J. Biol. Chem. 267:17047-17054(1992).
RN   [11]
RP   PROTEIN SEQUENCE OF 25-44; 529-538; 560-571 AND 671-686, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Fetal brain cortex;
RA   Lubec G., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 466-740 (ISOFORMS
RP   TAU-A/TAU-B/TAU-C/FETAL-TAU).
RA   Han J., Zhang J., Dong X.-P.;
RT   "Molecular interactions of recombinant neural protein tau with
RT   recombinant and native PrP proteins in vitro.";
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   PROTEIN SEQUENCE OF 543-551; 560-574; 576-584 AND 623-634,
RP   PHOSPHORYLATION AT SER-531; THR-534; THR-548; SER-552; SER-554;
RP   SER-579; SER-713 AND SER-739, UBIQUITINATION AT LYS-571; LYS-628 AND
RP   LYS-670, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16443603; DOI=10.1074/jbc.M512786200;
RA   Cripps D., Thomas S.N., Jeng Y., Yang F., Davies P., Yang A.J.;
RT   "Alzheimer disease-specific conformation of hyperphosphorylated paired
RT   helical filament-tau is polyubiquitinated through Lys-48, Lys-11, and
RT   Lys-6 ubiquitin conjugation.";
RL   J. Biol. Chem. 281:10825-10838(2006).
RN   [14]
RP   PROTEIN SEQUENCE OF 577-584; 608-611; 616-628; 639-648 AND 671-686,
RP   PHOSPHORYLATION AT SER-579; SER-610; SER-622; SER-641 AND SER-673, AND
RP   MUTAGENESIS.
RX   PubMed=7706316; DOI=10.1074/jbc.270.13.7679;
RA   Drewes G., Trinczek B., Illenberger S., Biernat J., Schmitt-Ulms G.,
RA   Meyer H.E., Mandelkow E.-M., Mandelkow E.;
RT   "Microtubule-associated protein/microtubule affinity-regulating kinase
RT   (p110mark). A novel protein kinase that regulates tau-microtubule
RT   interactions and dynamic instability by phosphorylation at the
RT   Alzheimer-specific site serine 262.";
RL   J. Biol. Chem. 270:7679-7688(1995).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 592-622 (ISOFORMS
RP   PNS-TAU/TAU-D/TAU-E/TAU-F).
RC   TISSUE=Brain;
RX   PubMed=2495000; DOI=10.1016/0006-291X(89)92240-7;
RA   Mori H., Hamada Y., Kawaguchi M., Honda T., Kondo J., Ihara Y.;
RT   "A distinct form of tau is selectively incorporated into Alzheimer's
RT   paired helical filaments.";
RL   Biochem. Biophys. Res. Commun. 159:1221-1226(1989).
RN   [16]
RP   PROTEIN SEQUENCE OF 251-264 AND 379-392, AND PHOSPHORYLATION AT
RP   SER-396.
RX   PubMed=1899488; DOI=10.1126/science.1899488;
RA   Lee V.M., Balin B.J., Otvos L. Jr., Trojanowski J.Q.;
RT   "A68: a major subunit of paired helical filaments and derivatized
RT   forms of normal Tau.";
RL   Science 251:675-678(1991).
RN   [17]
RP   PROTEIN SEQUENCE OF 616-712.
RX   PubMed=1915258;
RA   Jakes R., Novak M., Davison M., Wischik C.M.;
RT   "Identification of 3- and 4-repeat tau isoforms within the PHF in
RT   Alzheimer's disease.";
RL   EMBO J. 10:2725-2729(1991).
RN   [18]
RP   IDENTIFICATION (ISOFORM TAU-G), AND VARIANT HIS-441.
RX   PubMed=15365985; DOI=10.1002/humu.20086;
RA   Rademakers R., Cruts M., van Broeckhoven C.;
RT   "The role of tau (MAPT) in frontotemporal dementia and related
RT   tauopathies.";
RL   Hum. Mutat. 24:277-295(2004).
RN   [19]
RP   REVIEW.
RX   PubMed=1713721; DOI=10.1016/0166-2236(91)90105-4;
RA   Goedert M., Crowther R.A., Garner C.C.;
RT   "Molecular characterization of microtubule-associated proteins tau and
RT   MAP2.";
RL   Trends Neurosci. 14:193-199(1991).
RN   [20]
RP   PHOSPHORYLATION AT SER-554; SER-579; SER-602; SER-606 AND SER-669.
RX   PubMed=8999860;
RA   Paudel H.K.;
RT   "The regulatory Ser262 of microtubule-associated protein tau is
RT   phosphorylated by phosphorylase kinase.";
RL   J. Biol. Chem. 272:1777-1785(1997).
RN   [21]
RP   GLYCATION AT LYS-87; LYS-383; LYS-467; LYS-480; LYS-491; LYS-542;
RP   LYS-551; LYS-576; LYS-597; LYS-598; LYS-664; LYS-670 AND LYS-686, AND
RP   LACK OF GLYCATION AT LYS-24; LYS-44; LYS-67; LYS-381; LYS-391;
RP   LYS-392; LYS-394; LYS-465; LYS-497; LYS-507; LYS-541; LYS-557;
RP   LYS-571; LYS-574; LYS-584; LYS-591; LYS-607; LYS-611; LYS-615;
RP   LYS-628; LYS-634; LYS-638; LYS-648; LYS-657; LYS-660; LYS-687;
RP   LYS-692; LYS-700; LYS-702; LYS-712 AND LYS-755.
RX   PubMed=9326300;
RA   Nacharaju P., Ko L., Yen S.H.;
RT   "Characterization of in vitro glycation sites of tau.";
RL   J. Neurochem. 69:1709-1719(1997).
RN   [22]
RP   PHOSPHORYLATION, AND MUTAGENESIS.
RX   PubMed=9735171; DOI=10.1006/abbi.1998.0813;
RA   Sengupta A., Kabat J., Novak M., Wu Q., Grundke-Iqbal I., Iqbal K.;
RT   "Phosphorylation of tau at both Thr 231 and Ser 262 is required for
RT   maximal inhibition of its binding to microtubules.";
RL   Arch. Biochem. Biophys. 357:299-309(1998).
RN   [23]
RP   PHOSPHORYLATION AT THR-470; SER-516; SER-519; THR-529; SER-531;
RP   SER-552; SER-579; SER-713; SER-721 AND SER-739, AND MUTAGENESIS.
RX   PubMed=9614189; DOI=10.1091/mbc.9.6.1495;
RA   Illenberger S., Zheng-Fischhofer Q., Preuss U., Stamer K., Baumann K.,
RA   Trinczek B., Biernat J., Godemann R., Mandelkow E.-M., Mandelkow E.;
RT   "The endogenous and cell cycle-dependent phosphorylation of tau
RT   protein in living cells: implications for Alzheimer's disease.";
RL   Mol. Biol. Cell 9:1495-1512(1998).
RN   [24]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=10747907; DOI=10.1074/jbc.M000389200;
RA   Maas T., Eidenmueller J., Brandt R.;
RT   "Interaction of tau with the neural membrane cortex is regulated by
RT   phosphorylation at sites that are modified in paired helical
RT   filaments.";
RL   J. Biol. Chem. 275:15733-15740(2000).
RN   [25]
RP   PHOSPHORYLATION AT SER-519; THR-522; SER-713 AND SER-721 BY
RP   CSNK1D/CK1, AND INTERACTION WITH CSNK1D.
RX   PubMed=14761950; DOI=10.1074/jbc.M314116200;
RA   Li G., Yin H., Kuret J.;
RT   "Casein kinase 1 delta phosphorylates tau and disrupts its binding to
RT   microtubules.";
RL   J. Biol. Chem. 279:15938-15945(2004).
RN   [26]
RP   PHOSPHORYLATION AT THR-548 BY GSK3B.
RX   PubMed=14690523;
RA   Cho J.H., Johnson G.V.;
RT   "Primed phosphorylation of tau at Thr231 by glycogen synthase kinase
RT   3beta (GSK3beta) plays a critical role in regulating tau's ability to
RT   bind and stabilize microtubules.";
RL   J. Neurochem. 88:349-358(2004).
RN   [27]
RP   PHOSPHORYLATION AT TYR-18 BY FYN.
RX   PubMed=14999081; DOI=10.1523/JNEUROSCI.4162-03.2004;
RA   Lee G., Thangavel R., Sharma V.M., Litersky J.M., Bhaskar K.,
RA   Fang S.M., Do L.H., Andreadis A., Van Hoesen G., Ksiezak-Reding H.;
RT   "Phosphorylation of tau by fyn: implications for Alzheimer's
RT   disease.";
RL   J. Neurosci. 24:2304-2312(2004).
RN   [28]
RP   INTERACTION WITH SQSTM1, UBIQUITINATION, AND PROTEASOMAL DEGRADATION.
RX   PubMed=15953362; DOI=10.1111/j.1471-4159.2005.03181.x;
RA   Babu J.R., Geetha T., Wooten M.W.;
RT   "Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal
RT   degradation.";
RL   J. Neurochem. 94:192-203(2005).
RN   [29]
RP   PHOSPHORYLATION AT THR-498; SER-516; SER-519; THR-522; THR-529;
RP   SER-531; THR-548; SER-552; SER-579; SER-713; SER-721 AND SER-726, AND
RP   DEPHOSPHORYLATION AT THR-498; SER-516; SER-519; THR-522; THR-529;
RP   SER-531; THR-548; SER-552; SER-579; SER-713; SER-721 AND SER-726 BY
RP   PPP5C.
RX   PubMed=15546861; DOI=10.1074/jbc.M410775200;
RA   Liu F., Iqbal K., Grundke-Iqbal I., Rossie S., Gong C.X.;
RT   "Dephosphorylation of tau by protein phosphatase 5: impairment in
RT   Alzheimer's disease.";
RL   J. Biol. Chem. 280:1790-1796(2005).
RN   [30]
RP   PHOSPHORYLATION AT TYR-514; SER-515; SER-516; SER-519; SER-733;
RP   SER-739 AND THR-744.
RX   PubMed=16923168; DOI=10.1111/j.1471-4159.2006.04059.x;
RA   Sato S., Cerny R.L., Buescher J.L., Ikezu T.;
RT   "Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate,
RT   is involved in tau phosphorylation and aggregation.";
RL   J. Neurochem. 98:1573-1584(2006).
RN   [31]
RP   PHOSPHORYLATION AT SER-214 BY SGK1, AND INTERACTION WITH SGK1.
RX   PubMed=16982696; DOI=10.1128/MCB.01017-06;
RA   Yang Y.C., Lin C.H., Lee E.H.;
RT   "Serum- and glucocorticoid-inducible kinase 1 (SGK1) increases neurite
RT   formation through microtubule depolymerization by SGK1 and by SGK1
RT   phosphorylation of tau.";
RL   Mol. Cell. Biol. 26:8357-8370(2006).
RN   [32]
RP   PHOSPHORYLATION BY CSNK1D/CK1.
RX   PubMed=17562708; DOI=10.1074/jbc.M703269200;
RA   Hanger D.P., Byers H.L., Wray S., Leung K.-Y., Saxton M.J.,
RA   Seereeram A., Reynolds C.H., Ward M.A., Anderton B.H.;
RT   "Novel phosphorylation sites in tau from Alzheimer brain support a
RT   role for casein kinase 1 in disease pathogenesis.";
RL   J. Biol. Chem. 282:23645-23654(2007).
RN   [33]
RP   PHOSPHORYLATION AT THR-529 BY DYRK2.
RX   PubMed=18599021; DOI=10.1016/j.bcp.2008.05.021;
RA   Yoshida K.;
RT   "Role for DYRK family kinases on regulation of apoptosis.";
RL   Biochem. Pharmacol. 76:1389-1394(2008).
RN   [34]
RP   GLYCOSYLATION, PHOSPHORYLATION AT SER-516; SER-519; THR-522; THR-529;
RP   SER-531; THR-534; SER-579; SER-713; SER-721 AND SER-739, AND
RP   ASSOCIATION WITH ALZHEIMER DISEASE.
RX   PubMed=19451179; DOI=10.1093/brain/awp099;
RA   Liu F., Shi J., Tanimukai H., Gu J., Gu J., Grundke-Iqbal I.,
RA   Iqbal K., Gong C.X.;
RT   "Reduced O-GlcNAcylation links lower brain glucose metabolism and tau
RT   pathology in Alzheimer's disease.";
RL   Brain 132:1820-1832(2009).
RN   [35]
RP   INTERACTION WITH EPM2A.
RX   PubMed=19542233; DOI=10.1074/jbc.M109.009688;
RA   Puri R., Suzuki T., Yamakawa K., Ganesh S.;
RT   "Hyperphosphorylation and aggregation of Tau in laforin-deficient
RT   mice, an animal model for Lafora disease.";
RL   J. Biol. Chem. 284:22657-22663(2009).
RN   [36]
RP   GLYCOSYLATION AT SER-525; SER-555 AND SER-717, PHOSPHORYLATION AT
RP   SER-519; SER-713 SER-717 AND SER-721, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=21327254; DOI=10.1039/c0mb00337a;
RA   Smet-Nocca C., Broncel M., Wieruszeski J.M., Tokarski C., Hanoulle X.,
RA   Leroy A., Landrieu I., Rolando C., Lippens G., Hackenberger C.P.;
RT   "Identification of O-GlcNAc sites within peptides of the Tau protein
RT   and their impact on phosphorylation.";
RL   Mol. Biosyst. 7:1420-1429(2011).
RN   [37]
RP   FUNCTION, AND PHOSPHORYLATION AT THR-529 AND SER-579.
RX   PubMed=21985311; DOI=10.1111/j.1471-4159.2011.07523.x;
RA   Yoshida H., Goedert M.;
RT   "Phosphorylation of microtubule-associated protein tau by AMPK-related
RT   kinases.";
RL   J. Neurochem. 120:165-176(2012).
RN   [38]
RP   STRUCTURE BY NMR OF 542-554 IN COMPLEX WITH PIN1.
RX   PubMed=11313338; DOI=10.1074/jbc.M010327200;
RA   Wintjens R., Wieruszeski J.-M., Drobecq H., Rousselot-Pailley P.,
RA   Buee L., Lippens G., Landrieu I.;
RT   "1H NMR study on the binding of Pin1 Trp-Trp domain with
RT   phosphothreonine peptides.";
RL   J. Biol. Chem. 276:25150-25156(2001).
RN   [39]
RP   REVIEW ON VARIANTS.
RX   PubMed=10899436; DOI=10.1016/S0925-4439(00)00037-5;
RA   Goedert M., Spillantini M.G.;
RT   "Tau mutations in frontotemporal dementia FTDP-17 and their relevance
RT   for Alzheimer's disease.";
RL   Biochim. Biophys. Acta 1502:110-121(2000).
RN   [40]
RP   VARIANT FTD MET-654, AND VARIANTS ASN-285; ALA-289; HIS-441 AND
RP   PRO-447.
RX   PubMed=9629852; DOI=10.1002/ana.410430617;
RA   Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M.,
RA   Anderson L., Andreadis A., Wiederholt W.C., Raskind M.,
RA   Schellenberg G.D.;
RT   "Tau is a candidate gene for chromosome 17 frontotemporal dementia.";
RL   Ann. Neurol. 43:815-825(1998).
RN   [41]
RP   ERRATUM.
RA   Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M.,
RA   Anderson L., Andreadis A., Wiederholt W.C., Raskind M.,
RA   Schellenberg G.D.;
RL   Ann. Neurol. 44:428-428(1998).
RN   [42]
RP   VARIANT FTD LEU-618.
RX   PubMed=9736786; DOI=10.1093/hmg/7.11.1825;
RA   Dumanchin C., Camuzat A., Campion D., Verpillat P., Hannequin D.,
RA   Dubois B., Saugier-Veber P., Martin C., Penet C., Charbonnier F.,
RA   Agid Y., Frebourg T., Brice A.;
RT   "Segregation of a missense mutation in the microtubule-associated
RT   protein tau gene with familial frontotemporal dementia and
RT   parkinsonism.";
RL   Hum. Mol. Genet. 7:1825-1829(1998).
RN   [43]
RP   VARIANTS FTD VAL-589; LEU-618 AND TRP-723.
RX   PubMed=9641683; DOI=10.1038/31508;
RA   Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H.,
RA   Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., Hackett J.,
RA   Adamson J., Lincoln S., Dickson D., Davies P., Petersen R.C.,
RA   Stevens M., de Graaff E., Wauters E., van Baren J., Hillebrand M.,
RA   Joosse M., Kwon J.M., Nowotny P., Che L.K., Norton J., Morris J.C.,
RA   Reed L.A., Trojanowski J., Basun H., Lannfelt L., Neystat M., Fahn S.,
RA   Dark F., Tannenberg T., Dodd P.R., Hayward N., Kwok J.B.J.,
RA   Schofield P.R., Andreadis A., Snowden J., Craufurd D., Neary D.,
RA   Owen F., Oostra B.A., Hardy J., Goate A., van Swieten J., Mann D.,
RA   Lynch T., Heutink P.;
RT   "Association of missense and 5'-splice-site mutations in tau with the
RT   inherited dementia FTDP-17.";
RL   Nature 393:702-705(1998).
RN   [44]
RP   VARIANTS FTD LYS-596 AND LEU-618.
RX   PubMed=9789048; DOI=10.1073/pnas.95.22.13103;
RA   Clark L.N., Poorkaj P., Wszolek Z., Geschwind D.H., Nasreddine Z.S.,
RA   Miller B., Li D., Payami H., Awert F., Markopoulou K., Andreadis A.,
RA   D'Souza I., Lee V.M.-Y., Reed L., Trojanowski J.Q., Zhukareva V.,
RA   Bird T., Schellenberg G., Wilhelmsen K.C.;
RT   "Pathogenic implications of mutations in the tau gene in pallido-
RT   ponto-nigral degeneration and related neurodegenerative disorders
RT   linked to chromosome 17.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:13103-13107(1998).
RN   [45]
RP   VARIANT PPND LYS-596.
RX   PubMed=10412802; DOI=10.1007/s004010051052;
RA   Delisle M.-B., Murrell J.R., Richardson R., Trofatter J.A., Rascol O.,
RA   Soulages X., Mohr M., Calvas P., Ghetti B.;
RT   "A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a
RT   tauopathy with dementia and supranuclear palsy.";
RL   Acta Neuropathol. 98:62-77(1999).
RN   [46]
RP   VARIANTS FTD VAL-589; LYS-597 DEL; LEU-618 AND TRP-723.
RX   PubMed=9973279; DOI=10.1086/302256;
RA   Rizzu P., Van Swieten J.C., Joosse M., Hasegawa M., Stevens M.,
RA   Tibben A., Niermeijer M.F., Hillebrand M., Ravid R., Oostra B.A.,
RA   Goedert M., van Duijn C.M., Heutink P.;
RT   "High prevalence of mutations in the microtubule-associated protein
RT   tau in a population study of frontotemporal dementia in the
RT   Netherlands.";
RL   Am. J. Hum. Genet. 64:414-421(1999).
RN   [47]
RP   VARIANT FTD SER-618.
RX   PubMed=10553987;
RX   DOI=10.1002/1531-8249(199911)46:5<708::AID-ANA5>3.0.CO;2-K;
RA   Sperfeld A.D., Collatz M.B., Baier H., Palmbach M., Storch A.,
RA   Schwarz J., Tatsch K., Reske S., Joosse M., Heutink P., Ludolph A.C.;
RT   "FTDP-17: an early-onset phenotype with parkinsonism and epileptic
RT   seizures caused by a novel mutation.";
RL   Ann. Neurol. 46:708-715(1999).
RN   [48]
RP   VARIANTS FTD LEU-618; MET-654 AND TRP-723.
RX   PubMed=10214944; DOI=10.1016/S0014-5793(99)00294-X;
RA   Nacharaju P., Lewis J., Easson C., Yen S., Hackett J., Hutton M.,
RA   Yen S.H.;
RT   "Accelerated filament formation from tau protein with specific FTDP-17
RT   missense mutations.";
RL   FEBS Lett. 447:195-199(1999).
RN   [49]
RP   VARIANT FTD/CBD SER-618.
RX   PubMed=10374757; DOI=10.1097/00005072-199906000-00011;
RA   Bugiani O., Murrell J.R., Giaccone G., Hasegawa M., Ghigo G.,
RA   Tabaton M., Morbin M., Primavera A., Carella F., Solaro C.,
RA   Grisoli M., Savoiardo M., Spillantini M.G., Tagliavini F., Goedert M.,
RA   Ghetti B.;
RT   "Frontotemporal dementia and corticobasal degeneration in a family
RT   with a P301S mutation in tau.";
RL   J. Neuropathol. Exp. Neurol. 58:667-677(1999).
RN   [50]
RP   VARIANT PIDB ARG-706.
RX   PubMed=10604746; DOI=10.1097/00005072-199912000-00002;
RA   Murrell J.R., Spillantini M.G., Zolo P., Guazzelli M., Smith M.J.,
RA   Hasegawa M., Redi F., Crowther R.A., Pietrini P., Ghetti B.,
RA   Goedert M.;
RT   "Tau gene mutation G389R causes a tauopathy with abundant pick body-
RT   like inclusions and axonal deposits.";
RL   J. Neuropathol. Exp. Neurol. 58:1207-1226(1999).
RN   [51]
RP   VARIANT FTD LYS-596.
RX   PubMed=10489057; DOI=10.1212/WNL.53.4.864;
RA   Yasuda M., Kawamata T., Komure O., Kuno S., D'Souza I., Poorkaj P.,
RA   Kawai J., Tanimukai S., Yamamoto Y., Hasegawa H., Sasahara M.,
RA   Hazama F., Schellenberg G.D., Tanaka C.;
RT   "A mutation in the microtubule-associated protein tau in pallido-
RT   nigro-luysian degeneration.";
RL   Neurology 53:864-868(1999).
RN   [52]
RP   VARIANTS PSNP1 ASN-285 AND ALA-289.
RX   PubMed=10534245; DOI=10.1212/WNL.53.7.1421;
RA   Higgins J.J., Adler R.L., Loveless J.M.;
RT   "Mutational analysis of the tau gene in progressive supranuclear
RT   palsy.";
RL   Neurology 53:1421-1424(1999).
RN   [53]
RP   VARIANT FTD ASN-622.
RX   PubMed=10208578; DOI=10.1097/00001756-199902250-00010;
RA   Iijima M., Tabira T., Poorkaj P., Schellenberg G.D., Trojanowski J.Q.,
RA   Lee V.M.-Y., Schmidt M.L., Takahashi K., Nabika T., Matsumoto T.,
RA   Yamashita Y., Yoshioka S., Ishino H.;
RT   "A distinct familial presenile dementia with a novel missense mutation
RT   in the tau gene.";
RL   NeuroReport 10:497-501(1999).
RN   [54]
RP   VARIANT FTD VAL-659.
RX   PubMed=11117541;
RX   DOI=10.1002/1531-8249(200012)48:6<850::AID-ANA5>3.0.CO;2-V;
RA   Lippa C.F., Zhukareva V., Kawarai T., Uryu K., Shafiq M., Nee L.E.,
RA   Grafman J., Liang Y., St George-Hyslop P.H., Trojanowski J.Q.,
RA   Lee V.M.-Y.;
RT   "Frontotemporal dementia with novel tau pathology and a Glu342Val tau
RT   mutation.";
RL   Ann. Neurol. 48:850-858(2000).
RN   [55]
RP   VARIANTS PIDB THR-574 AND ARG-706, AND CHARACTERIZATION OF VARIANTS
RP   PIDB THR-574 AND ARG-706.
RX   PubMed=11117542;
RX   DOI=10.1002/1531-8249(200012)48:6<859::AID-ANA6>3.3.CO;2-T;
RA   Pickering-Brown S., Baker M., Yen S.-H., Liu W.-K., Hasegawa M.,
RA   Cairns N., Lantos P.L., Rossor M., Iwatsubo T., Davies Y., Allsop D.,
RA   Furlong R., Owen F., Hardy J., Mann D., Hutton M.;
RT   "Pick's disease is associated with mutations in the tau gene.";
RL   Ann. Neurol. 48:859-867(2000).
RN   [56]
RP   VARIANT PIDB THR-574.
RX   PubMed=11089577;
RA   Rizzini C., Goedert M., Hodges J.R., Smith M.J., Jakes R., Hills R.,
RA   Xuereb J.H., Crowther R.A., Spillantini M.G.;
RT   "Tau gene mutation K257T causes a tauopathy similar to Pick's
RT   disease.";
RL   J. Neuropathol. Exp. Neurol. 59:990-1001(2000).
RN   [57]
RP   VARIANT FTD LYS-596.
RX   PubMed=10802785; DOI=10.1212/WNL.54.9.1787;
RA   Arima K., Kowalska A., Hasegawa M., Mukoyama M., Watanabe R.,
RA   Kawai M., Takahashi K., Iwatsubo T., Tabira T., Sunohara N.;
RT   "Two brothers with frontotemporal dementia and parkinsonism with an
RT   N279K mutation of the tau gene.";
RL   Neurology 54:1787-1795(2000).
RN   [58]
RP   VARIANT FTD SER-618.
RX   PubMed=11071507; DOI=10.1212/WNL.55.8.1224;
RA   Yasuda M., Yokoyama K., Nakayasu T., Nishimura Y., Matsui M.,
RA   Yokoyama T., Miyoshi K., Tanaka C.;
RT   "A Japanese patient with frontotemporal dementia and parkinsonism by a
RT   tau P301S mutation.";
RL   Neurology 55:1224-1227(2000).
RN   [59]
RP   VARIANT FTD HIS-613.
RX   PubMed=11585254;
RA   Iseki E., Matsumura T., Marui W., Hino H., Odawara T., Sugiyama N.,
RA   Suzuki K., Sawada H., Arai T., Kosaka K.;
RT   "Familial frontotemporal dementia and parkinsonism with a novel N296H
RT   mutation in exon 10 of the tau gene and a widespread tau accumulation
RT   in the glial cells.";
RL   Acta Neuropathol. 102:285-292(2001).
RN   [60]
RP   VARIANT PSNP1 ASN-613 DEL.
RX   PubMed=11220749;
RX   DOI=10.1002/1531-8249(20010201)49:2<263::AID-ANA50>3.0.CO;2-K;
RA   Pastor P., Pastor E., Carnero C., Vela R., Garcia T., Amer G.,
RA   Tolosa E., Oliva R.;
RT   "Familial atypical progressive supranuclear palsy associated with
RT   homozygosity for the delN296 mutation in the tau gene.";
RL   Ann. Neurol. 49:263-267(2001).
RN   [61]
RP   VARIANT PIDB ILE-686, AND CHARACTERIZATION OF VARIANT PIDB ILE-686.
RX   PubMed=11601501; DOI=10.1002/ana.1223;
RA   Neumann M., Schulz-Schaeffer W., Crowther R.A., Smith M.J.,
RA   Spillantini M.G., Goedert M., Kretzschmar H.A.;
RT   "Pick's disease associated with the novel Tau gene mutation K369I.";
RL   Ann. Neurol. 50:503-513(2001).
RN   [62]
RP   CHARACTERIZATION OF VARIANT FTD TRP-723.
RX   PubMed=11278002; DOI=10.1016/S0014-5793(01)02267-0;
RA   Connell J.W., Gibb G.M., Betts J.C., Blackstock W.P., Gallo J.-M.,
RA   Lovestone S., Hutton M., Anderton B.H.;
RT   "Effects of FTDP-17 mutations on the in vitro phosphorylation of tau
RT   by glycogen synthase kinase 3beta identified by mass spectrometry
RT   demonstrate certain mutations exert long-range conformational
RT   changes.";
RL   FEBS Lett. 493:40-44(2001).
RN   [63]
RP   VARIANT FTD LYS-596.
RX   PubMed=12473774; DOI=10.1212/01.WNL.0000038909.49164.4B;
RA   Tsuboi Y., Baker M., Hutton M.L., Uitti R.J., Rascol O.,
RA   Delisle M.-B., Soulages X., Murrell J.R., Ghetti B., Yasuda M.,
RA   Komure O., Kuno S., Arima K., Sunohara N., Kobayashi T., Mizuno Y.,
RA   Wszolek Z.K.;
RT   "Clinical and genetic studies of families with the tau N279K mutation
RT   (FTDP-17).";
RL   Neurology 59:1791-1793(2002).
RN   [64]
RP   VARIANT PIDB PHE-637, AND CHARACTERIZATION OF VARIANT PIDB PHE-637.
RX   PubMed=11891833; DOI=10.1002/ana.10140;
RA   Rosso S.M., Van Herpen E., Deelen W., Kamphorst W., Severijnen L.-A.,
RA   Willemsen R., Ravid R., Niermeijer M.F., Dooijes D., Smith M.J.,
RA   Goedert M., Heutink P., Van Swieten J.C.;
RT   "A novel tau mutation, S320F, causes a tauopathy with inclusions
RT   similar to those in Pick's disease.";
RL   Ann. Neurol. 51:373-376(2002).
RN   [65]
RP   VARIANT FTD HIS-5, AND CHARACTERIZATION OF VARIANT FTD HIS-5.
RX   PubMed=11921059; DOI=10.1002/ana.10163;
RA   Hayashi S., Toyoshima Y., Hasegawa M., Umeda Y., Wakabayashi K.,
RA   Tokiguchi S., Iwatsubo T., Takahashi H.;
RT   "Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau
RT   gene mutation.";
RL   Ann. Neurol. 51:525-530(2002).
RN   [66]
RP   VARIANT PSNP1 LEU-5, AND CHARACTERIZATION OF VARIANT PSNP1 LEU-5.
RX   PubMed=12325083; DOI=10.1002/ana.10340;
RA   Poorkaj P., Muma N.A., Zhukareva V., Cochran E.J., Shannon K.M.,
RA   Hurtig H., Koller W.C., Bird T.D., Trojanowski J.Q., Lee V.M.-Y.,
RA   Schellenberg G.D.;
RT   "An R5L tau mutation in a subject with a progressive supranuclear
RT   palsy phenotype.";
RL   Ann. Neurol. 52:511-516(2002).
RN   [67]
RP   CHARACTERIZATION OF VARIANTS FTD ASN-613 DEL AND HIS-613.
RX   PubMed=11906000; DOI=10.1046/j.0022-3042.2001.00729.x;
RA   Yoshida H., Crowther R.A., Goedert M.;
RT   "Functional effects of tau gene mutations deltaN296 and N296H.";
RL   J. Neurochem. 80:548-551(2002).
RN   [68]
RP   VARIANT FTD TRP-723.
RX   PubMed=11889249; DOI=10.1212/WNL.58.5.811;
RA   Saito Y., Geyer A., Sasaki R., Kuzuhara S., Nanba E., Miyasaka T.,
RA   Suzuki K., Murayama S.;
RT   "Early-onset, rapidly progressive familial tauopathy with R406W
RT   mutation.";
RL   Neurology 58:811-813(2002).
RN   [69]
RP   VARIANT FTD VAL-583, AND CHARACTERIZATION OF VARIANT FTD VAL-583.
RX   PubMed=12509859; DOI=10.1002/ana.10447;
RA   Kobayashi T., Ota S., Tanaka K., Ito Y., Hasegawa M., Umeda Y.,
RA   Motoi Y., Takanashi M., Yasuhara M., Anno M., Mizuno Y., Mori H.;
RT   "A novel L266V mutation of the tau gene causes frontotemporal dementia
RT   with a unique tau pathology.";
RL   Ann. Neurol. 53:133-137(2003).
RN   [70]
RP   VARIANT FATAL RESPIRATORY HYPOVENTILATION LEU-669, AND
RP   CHARACTERIZATION OF VARIANT FATAL RESPIRATORY HYPOVENTILATION LEU-669.
RX   PubMed=14595660; DOI=10.1002/ana.10747;
RA   Nicholl D.J., Greenstone M.A., Clarke C.E., Rizzu P., Crooks D.,
RA   Crowe A., Trojanowski J.Q., Lee V.M.-Y., Heutink P.;
RT   "An English kindred with a novel recessive tauopathy and respiratory
RT   failure.";
RL   Ann. Neurol. 54:682-686(2003).
RN   [71]
RP   VARIANT FTDP17/ALZHEIMER DISEASE TRP-723.
RX   PubMed=14517953; DOI=10.1002/humu.10269;
RA   Rademakers R., Dermaut B., Peeters K., Cruts M., Heutink P., Goate A.,
RA   Van Broeckhoven C.;
RT   "Tau (MAPT) mutation arg406trp presenting clinically with Alzheimer
RT   disease does not share a common founder in western Europe.";
RL   Hum. Mutat. 22:409-411(2003).
RN   [72]
RP   VARIANT ATYPICAL PSNP1 ASN-613 DEL.
RX   PubMed=14991829; DOI=10.1002/ana.20006;
RA   Rossi G., Gasparoli E., Pasquali C., Di Fede G., Testa D.,
RA   Albanese A., Bracco F., Tagliavini F.;
RT   "Progressive supranuclear palsy and Parkinson's disease in a family
RT   with a new mutation in the tau gene.";
RL   Ann. Neurol. 55:448-448(2004).
RN   [73]
RP   VARIANT PSNP1/ATYPICAL PSNP1 ASN-613 DEL.
RX   PubMed=14991828; DOI=10.1002/ana.20025;
RA   Oliva R., Pastor P.;
RT   "Tau gene delN296 mutation, Parkinson's disease, and atypical
RT   supranuclear palsy.";
RL   Ann. Neurol. 55:448-449(2004).
RN   [74]
RP   VARIANT FTD SER-618.
RX   PubMed=16240366; DOI=10.1002/ana.20668;
RA   Yasuda M., Nakamura Y., Kawamata T., Kaneyuki H., Maeda K., Komure O.;
RT   "Phenotypic heterogeneity within a new family with the MAPT P301S
RT   mutation.";
RL   Ann. Neurol. 58:920-928(2005).
RN   [75]
RP   VARIANT PSNP1 VAL-620.
RX   PubMed=16157753; DOI=10.1001/archneur.62.9.1444;
RA   Ros R., Thobois S., Streichenberger N., Kopp N., Sanchez M.P.,
RA   Perez M., Hoenicka J., Avila J., Honnorat J., de Yebenes J.G.;
RT   "A new mutation of the tau gene, G303V, in early-onset familial
RT   progressive supranuclear palsy.";
RL   Arch. Neurol. 62:1444-1450(2005).
RN   [76]
RP   VARIANT FTD MET-634.
RX   PubMed=15883319; DOI=10.1212/01.WNL.0000160116.65034.12;
RA   Zarranz J.J., Ferrer I., Lezcano E., Forcadas M.I., Eizaguirre B.,
RA   Atares B., Puig B., Gomez-Esteban J.C., Fernandez-Maiztegui C.,
RA   Rouco I., Perez-Concha T., Fernandez M., Rodriguez O.,
RA   Rodriguez-Martinez A.B., de Pancorbo M.M., Pastor P., Perez-Tur J.;
RT   "A novel mutation (K317M) in the MAPT gene causes FTDP and motor
RT   neuron disease.";
RL   Neurology 64:1578-1585(2005).
RN   [77]
RP   VARIANTS MET-17; ALA-30 AND ILE-617.
RX   PubMed=20020531; DOI=10.1002/humu.21152;
RA   Guerreiro R.J., Washecka N., Hardy J., Singleton A.;
RT   "A thorough assessment of benign genetic variability in GRN and
RT   MAPT.";
RL   Hum. Mutat. 31:E1126-E1140(2010).
CC   -!- FUNCTION: Promotes microtubule assembly and stability, and might
CC       be involved in the establishment and maintenance of neuronal
CC       polarity. The C-terminus binds axonal microtubules while the N-
CC       terminus binds neural plasma membrane components, suggesting that
CC       tau functions as a linker protein between both. Axonal polarity is
CC       predetermined by TAU/MAPT localization (in the neuronal cell) in
CC       the domain of the cell body defined by the centrosome. The short
CC       isoforms allow plasticity of the cytoskeleton whereas the longer
CC       isoforms may preferentially play a role in its stabilization.
CC       {ECO:0000269|PubMed:21985311}.
CC   -!- SUBUNIT: Interacts with PSMC2 through SQSTM1 (By similarity).
CC       Interacts with SQSTM1 when polyubiquitinated. Interacts with FKBP4
CC       (By similarity). Binds to CSNK1D. Interacts with SGK1. Interacts
CC       with EPM2A; the interaction dephosphorylates MAPT at Ser-396.
CC       {ECO:0000250, ECO:0000269|PubMed:11313338,
CC       ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15953362,
CC       ECO:0000269|PubMed:16982696, ECO:0000269|PubMed:19542233}.
CC   -!- INTERACTION:
CC       P02649:APOE; NbExp=3; IntAct=EBI-366182, EBI-9209835;
CC       P05067:APP; NbExp=9; IntAct=EBI-366182, EBI-77613;
CC       O00499-1:BIN1; NbExp=5; IntAct=EBI-6926270, EBI-6926280;
CC       Q14203:DCTN1; NbExp=8; IntAct=EBI-366233, EBI-724352;
CC       P49841:GSK3B; NbExp=9; IntAct=EBI-366233, EBI-373586;
CC       P08238:HSP90AB1; NbExp=4; IntAct=EBI-366233, EBI-352572;
CC       Q5S007:LRRK2; NbExp=9; IntAct=EBI-366233, EBI-5323863;
CC       Q7KZI7:MARK2; NbExp=2; IntAct=EBI-366233, EBI-516560;
CC       P04156:PRNP; NbExp=2; IntAct=EBI-366182, EBI-977302;
CC       P43004:SLC1A2; NbExp=4; IntAct=EBI-366182, EBI-3440986;
CC       P37840:SNCA; NbExp=3; IntAct=EBI-366233, EBI-985879;
CC       Q9UNE7:STUB1; NbExp=2; IntAct=EBI-366182, EBI-357085;
CC       P63104:YWHAZ; NbExp=9; IntAct=EBI-7145070, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000269|PubMed:10747907}. Cell membrane
CC       {ECO:0000269|PubMed:10747907}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:10747907}; Cytoplasmic side
CC       {ECO:0000269|PubMed:10747907}. Cytoplasm, cytoskeleton
CC       {ECO:0000269|PubMed:10747907}. Cell projection, axon
CC       {ECO:0000269|PubMed:10747907}. Note=Mostly found in the axons of
CC       neurons, in the cytosol and in association with plasma membrane
CC       components.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=9;
CC         Comment=Additional isoforms seem to exist. Isoforms differ from
CC         each other by the presence or absence of up to 5 of the 15
CC         exons. One of these optional exons contains the additional
CC         tau/MAP repeat.;
CC       Name=PNS-tau;
CC         IsoId=P10636-1; Sequence=Displayed;
CC       Name=Fetal-tau;
CC         IsoId=P10636-2; Sequence=VSP_003176, VSP_003177, VSP_003179,
CC                                  VSP_003180, VSP_003181;
CC       Name=Tau-A;
CC         IsoId=P10636-3; Sequence=VSP_003175, VSP_003176, VSP_003177,
CC                                  VSP_003178, VSP_003179, VSP_003180,
CC                                  VSP_003181;
CC       Name=Tau-B;
CC         IsoId=P10636-4; Sequence=VSP_003177, VSP_003179, VSP_003180,
CC                                  VSP_003181;
CC       Name=Tau-C; Synonyms=Tau-3;
CC         IsoId=P10636-5; Sequence=VSP_003179, VSP_003180, VSP_003181;
CC       Name=Tau-D;
CC         IsoId=P10636-6; Sequence=VSP_003176, VSP_003177, VSP_003179,
CC                                  VSP_003180;
CC       Name=Tau-E;
CC         IsoId=P10636-7; Sequence=VSP_003177, VSP_003179, VSP_003180;
CC       Name=Tau-F; Synonyms=Tau-4;
CC         IsoId=P10636-8; Sequence=VSP_003179, VSP_003180;
CC       Name=Tau-G;
CC         IsoId=P10636-9; Sequence=VSP_026780;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau is
CC       expressed in the peripheral nervous system while the others are
CC       expressed in the central nervous system.
CC   -!- DEVELOPMENTAL STAGE: Four-repeat (type II) TAU/MAPT is expressed
CC       in an adult-specific manner and is not found in fetal brain,
CC       whereas three-repeat (type I) TAU/MAPT is found in both adult and
CC       fetal brain.
CC   -!- DOMAIN: The tau/MAP repeat binds to tubulin. Type I isoforms
CC       contain 3 repeats while type II isoforms contain 4 repeats.
CC   -!- PTM: Phosphorylation at serine and threonine residues in S-P or T-
CC       P motifs by proline-directed protein kinases (PDPK1: CDK1, CDK5,
CC       GSK3, MAPK) (only 2-3 sites per protein in interphase, seven-fold
CC       increase in mitosis, and in the form associated with paired
CC       helical filaments (PHF-tau)), and at serine residues in K-X-G-S
CC       motifs by MAP/microtubule affinity-regulating kinase (MARK1 or
CC       MARK2), causing detachment from microtubules, and their
CC       disassembly. Phosphorylation decreases with age. Phosphorylation
CC       within tau/MAP's repeat domain or in flanking regions seems to
CC       reduce tau/MAP's interaction with, respectively, microtubules or
CC       plasma membrane components. Phosphorylation on Ser-610, Ser-622,
CC       Ser-641 and Ser-673 in several isoforms during mitosis.
CC       Phosphorylation at Ser-548 by GSK3B reduces ability to bind and
CC       stabilize microtubules. Phosphorylation at Ser-579 by BRSK1 and
CC       BRSK2 in neurons affects ability to bind microtubules and plays a
CC       role in neuron polarization. Phosphorylated at Ser-554, Ser-579,
CC       Ser-602, Ser-606 and Ser-669 by PHK. Phosphorylation at Ser-214 by
CC       SGK1 mediates microtubule depolymerization and neurite formation
CC       in hippocampal neurons. There is a reciprocal down-regulation of
CC       phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717
CC       completely abolishes the O-GlcNAcylation on this site, while
CC       phosphorylation on Ser-713 and Ser-721 reduces glycosylation by a
CC       factor of 2 and 4 respectively. Phosphorylation on Ser-721 is
CC       reduced by about 41.5% by GlcNAcylation on Ser-717.
CC       Dephosphorylated at several serine and threonine residues by the
CC       serine/threonine phosphatase PPP5C. {ECO:0000269|PubMed:14690523,
CC       ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,
CC       ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:16982696,
CC       ECO:0000269|PubMed:19451179, ECO:0000269|PubMed:21327254,
CC       ECO:0000269|PubMed:21985311, ECO:0000269|PubMed:7706316,
CC       ECO:0000269|PubMed:8999860, ECO:0000269|PubMed:9614189}.
CC   -!- PTM: Polyubiquitinated. Requires functional TRAF6 and may provoke
CC       SQSTM1-dependent degradation by the proteasome (By similarity).
CC       PHF-tau can be modified by three different forms of
CC       polyubiquitination. 'Lys-48'-linked polyubiquitination is the
CC       major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination
CC       also occur. {ECO:0000250, ECO:0000269|PubMed:15953362,
CC       ECO:0000269|PubMed:16443603}.
CC   -!- PTM: O-glycosylated. O-GlcNAcylation content is around 8.2%. There
CC       is reciprocal down-regulation of phosphorylation and O-
CC       GlcNAcylation. Phosphorylation on Ser-717 completely abolishes the
CC       O-GlcNAcylation on this site, while phosphorylation on Ser-713 and
CC       Ser-721 reduces O-GlcNAcylation by a factor of 2 and 4
CC       respectively. O-GlcNAcylation on Ser-717 decreases the
CC       phosphorylation on Ser-721 by about 41.5%.
CC       {ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,
CC       ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:19451179,
CC       ECO:0000269|PubMed:21327254, ECO:0000269|PubMed:9614189}.
CC   -!- PTM: Glycation of PHF-tau, but not normal brain TAU/MAPT.
CC       Glycation is a non-enzymatic post-translational modification that
CC       involves a covalent linkage between a sugar and an amino group of
CC       a protein molecule forming ketoamine. Subsequent oxidation,
CC       fragmentation and/or cross-linking of ketoamine leads to the
CC       production of advanced glycation endproducts (AGES). Glycation may
CC       play a role in stabilizing PHF aggregation leading to tangle
CC       formation in AD.
CC   -!- DISEASE: Note=In Alzheimer disease, the neuronal cytoskeleton in
CC       the brain is progressively disrupted and replaced by tangles of
CC       paired helical filaments (PHF) and straight filaments, mainly
CC       composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-
CC       TAU). O-GlcNAcylation is greatly reduced in Alzheimer disease
CC       brain cerebral cortex leading to an increase in TAU/MAPT
CC       phosphorylations. {ECO:0000269|PubMed:14517953}.
CC   -!- DISEASE: Frontotemporal dementia (FTD) [MIM:600274]: A form of
CC       dementia characterized by pathologic finding of frontotemporal
CC       lobar degeneration, presenile dementia with behavioral changes,
CC       deterioration of cognitive capacities and loss of memory. In some
CC       cases, parkinsonian symptoms are prominent. Neuropathological
CC       changes include frontotemporal atrophy often associated with
CC       atrophy of the basal ganglia, substantia nigra, amygdala. In most
CC       cases, protein tau deposits are found in glial cells and/or
CC       neurons. {ECO:0000269|PubMed:10208578,
CC       ECO:0000269|PubMed:10214944, ECO:0000269|PubMed:10489057,
CC       ECO:0000269|PubMed:10553987, ECO:0000269|PubMed:10802785,
CC       ECO:0000269|PubMed:11071507, ECO:0000269|PubMed:11117541,
CC       ECO:0000269|PubMed:11585254, ECO:0000269|PubMed:11889249,
CC       ECO:0000269|PubMed:11921059, ECO:0000269|PubMed:12473774,
CC       ECO:0000269|PubMed:12509859, ECO:0000269|PubMed:15883319,
CC       ECO:0000269|PubMed:16240366, ECO:0000269|PubMed:9629852,
CC       ECO:0000269|PubMed:9641683, ECO:0000269|PubMed:9736786,
CC       ECO:0000269|PubMed:9789048, ECO:0000269|PubMed:9973279}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Pick disease of the brain (PIDB) [MIM:172700]: A rare
CC       form of dementia pathologically defined by severe atrophy,
CC       neuronal loss and gliosis. It is characterized by the occurrence
CC       of tau-positive inclusions, swollen neurons (Pick cells) and
CC       argentophilic neuronal inclusions known as Pick bodies that
CC       disproportionally affect the frontal and temporal cortical
CC       regions. Clinical features include aphasia, apraxia, confusion,
CC       anomia, memory loss and personality deterioration.
CC       {ECO:0000269|PubMed:10604746, ECO:0000269|PubMed:11089577,
CC       ECO:0000269|PubMed:11117542, ECO:0000269|PubMed:11601501,
CC       ECO:0000269|PubMed:11891833}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Defects in MAPT are a cause of corticobasal
CC       degeneration (CBD). It is marked by extrapyramidal signs and
CC       apraxia and can be associated with memory loss. Neuropathologic
CC       features may overlap Alzheimer disease, progressive supranuclear
CC       palsy, and Parkinson disease.
CC   -!- DISEASE: Progressive supranuclear palsy 1 (PSNP1) [MIM:601104]:
CC       Characterized by akinetic-rigid syndrome, supranuclear gaze palsy,
CC       pyramidal tract dysfunction, pseudobulbar signs and cognitive
CC       capacities deterioration. Neurofibrillary tangles and gliosis but
CC       no amyloid plaques are found in diseased brains. Most cases appear
CC       to be sporadic, with a significant association with a common
CC       haplotype including the MAPT gene and the flanking regions.
CC       Familial cases show an autosomal dominant pattern of transmission
CC       with incomplete penetrance; genetic analysis of a few cases showed
CC       the occurrence of tau mutations, including a deletion of Asn-613.
CC       {ECO:0000269|PubMed:10534245, ECO:0000269|PubMed:11220749,
CC       ECO:0000269|PubMed:12325083, ECO:0000269|PubMed:14991828,
CC       ECO:0000269|PubMed:14991829, ECO:0000269|PubMed:16157753}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Parkinson-dementia syndrome (PARDE) [MIM:260540]: A
CC       syndrome characterized by parkinsonism, tremor, rigidity,
CC       dementia, ophthalmoparesis and pyramidal signs. Neurofibrillary
CC       degeneration occurs in the hippocampus, basal ganglia and
CC       brainstem nuclei. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Contains 4 Tau/MAP repeats. {ECO:0000255|PROSITE-
CC       ProRule:PRU00824}.
CC   -!- WEB RESOURCE: Name=Alzforum; Note=MAPT mutations;
CC       URL="http://alzforum.org/mutations/search?genes%5B%5D=492";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Vita minima - Issue 68
CC       of March 2006;
CC       URL="http://web.expasy.org/spotlight/back_issues/068";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Tau protein entry;
CC       URL="https://en.wikipedia.org/wiki/Tau_protein";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J03778; AAA60615.1; -; mRNA.
DR   EMBL; X14474; CAA32636.1; -; mRNA.
DR   EMBL; AF047863; AAC04277.1; -; Genomic_DNA.
DR   EMBL; AF027491; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF047856; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF047857; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF027492; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF047858; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF027493; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF047859; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF047860; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF047862; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF027494; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF027495; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF027496; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF027491; AAC04278.1; -; Genomic_DNA.
DR   EMBL; AF027492; AAC04278.1; JOINED; Genomic_DNA.
DR   EMBL; AF027493; AAC04278.1; JOINED; Genomic_DNA.
DR   EMBL; AF047860; AAC04278.1; JOINED; Genomic_DNA.
DR   EMBL; AF047862; AAC04278.1; JOINED; Genomic_DNA.
DR   EMBL; AF027495; AAC04278.1; JOINED; Genomic_DNA.
DR   EMBL; AF027496; AAC04278.1; JOINED; Genomic_DNA.
DR   EMBL; AF047863; AAC04278.1; JOINED; Genomic_DNA.
DR   EMBL; AF027491; AAC04279.1; -; Genomic_DNA.
DR   EMBL; AF047856; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF047857; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF027492; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF027493; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF047860; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF047862; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF027494; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF027495; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF027496; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF047863; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF047861; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AY730549; AAU45390.1; -; mRNA.
DR   EMBL; BT006772; AAP35418.1; -; mRNA.
DR   EMBL; AC004139; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC010792; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC217771; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC217779; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000558; AAH00558.1; -; mRNA.
DR   EMBL; BC098281; AAH98281.1; -; mRNA.
DR   EMBL; BC099721; AAH99721.1; -; mRNA.
DR   EMBL; BC101936; AAI01937.1; -; mRNA.
DR   EMBL; BC114504; AAI14505.1; -; mRNA.
DR   EMBL; BC114948; AAI14949.1; -; mRNA.
DR   EMBL; AY526356; AAS17881.1; -; mRNA.
DR   EMBL; M25298; AAA57264.1; -; mRNA.
DR   EMBL; BN000503; CAG26750.1; -; mRNA.
DR   CCDS; CCDS11499.1; -. [P10636-8]
DR   CCDS; CCDS11500.1; -. [P10636-6]
DR   CCDS; CCDS11501.1; -. [P10636-1]
DR   CCDS; CCDS11502.1; -. [P10636-2]
DR   CCDS; CCDS45715.1; -. [P10636-9]
DR   CCDS; CCDS45716.1; -. [P10636-7]
DR   CCDS; CCDS56033.1; -. [P10636-5]
DR   PIR; I52232; I52232.
DR   PIR; JS0370; QRHUT1.
DR   PIR; PN0001; QRHUT2.
DR   PIR; S26663; S26663.
DR   RefSeq; NP_001116538.2; NM_001123066.3. [P10636-9]
DR   RefSeq; NP_001116539.1; NM_001123067.3. [P10636-7]
DR   RefSeq; NP_001190181.1; NM_001203252.1. [P10636-5]
DR   RefSeq; NP_005901.2; NM_005910.5. [P10636-8]
DR   RefSeq; NP_058518.1; NM_016834.4. [P10636-6]
DR   RefSeq; NP_058519.3; NM_016835.4. [P10636-1]
DR   RefSeq; NP_058525.1; NM_016841.4. [P10636-2]
DR   UniGene; Hs.101174; -.
DR   PDB; 1I8H; NMR; -; A=542-554.
DR   PDB; 2MZ7; NMR; -; A=584-629.
DR   PDB; 2ON9; X-ray; 1.51 A; A/B=623-628.
DR   PDB; 3OVL; X-ray; 1.81 A; A=623-628.
DR   PDB; 4E0M; X-ray; 1.75 A; A/B/C/D=622-634.
DR   PDB; 4E0N; X-ray; 1.65 A; A/B/C/D=622-634.
DR   PDB; 4E0O; X-ray; 1.82 A; A/B/C/D=622-634.
DR   PDB; 4FL5; X-ray; 1.90 A; P/Q=527-536.
DR   PDB; 4GLR; X-ray; 1.90 A; A/B=541-557.
DR   PDB; 4NP8; X-ray; 1.51 A; A=623-628.
DR   PDB; 4TQE; X-ray; 1.60 A; A=532-547.
DR   PDBsum; 1I8H; -.
DR   PDBsum; 2MZ7; -.
DR   PDBsum; 2ON9; -.
DR   PDBsum; 3OVL; -.
DR   PDBsum; 4E0M; -.
DR   PDBsum; 4E0N; -.
DR   PDBsum; 4E0O; -.
DR   PDBsum; 4FL5; -.
DR   PDBsum; 4GLR; -.
DR   PDBsum; 4NP8; -.
DR   PDBsum; 4TQE; -.
DR   DisProt; DP00126; -.
DR   ProteinModelPortal; P10636; -.
DR   BioGrid; 110308; 93.
DR   DIP; DIP-29753N; -.
DR   IntAct; P10636; 38.
DR   MINT; MINT-134394; -.
DR   STRING; 9606.ENSP00000340820; -.
DR   BindingDB; P10636; -.
DR   ChEMBL; CHEMBL1293224; -.
DR   DrugBank; DB01248; Docetaxel.
DR   DrugBank; DB01229; Paclitaxel.
DR   PhosphoSite; P10636; -.
DR   BioMuta; MAPT; -.
DR   DMDM; 334302961; -.
DR   MaxQB; P10636; -.
DR   PaxDb; P10636; -.
DR   PRIDE; P10636; -.
DR   DNASU; 4137; -.
DR   Ensembl; ENST00000262410; ENSP00000262410; ENSG00000186868. [P10636-1]
DR   Ensembl; ENST00000334239; ENSP00000334886; ENSG00000186868. [P10636-2]
DR   Ensembl; ENST00000340799; ENSP00000340438; ENSG00000186868. [P10636-7]
DR   Ensembl; ENST00000344290; ENSP00000340820; ENSG00000186868. [P10636-9]
DR   Ensembl; ENST00000351559; ENSP00000303214; ENSG00000186868. [P10636-8]
DR   Ensembl; ENST00000415613; ENSP00000410838; ENSG00000186868. [P10636-9]
DR   Ensembl; ENST00000420682; ENSP00000413056; ENSG00000186868. [P10636-7]
DR   Ensembl; ENST00000431008; ENSP00000389250; ENSG00000186868. [P10636-5]
DR   Ensembl; ENST00000446361; ENSP00000408975; ENSG00000186868. [P10636-6]
DR   Ensembl; ENST00000535772; ENSP00000443028; ENSG00000186868. [P10636-5]
DR   Ensembl; ENST00000571987; ENSP00000458742; ENSG00000186868. [P10636-1]
DR   Ensembl; ENST00000574436; ENSP00000460965; ENSG00000186868. [P10636-8]
DR   Ensembl; ENST00000612872; ENSP00000478602; ENSG00000277956. [P10636-7]
DR   Ensembl; ENST00000613360; ENSP00000483784; ENSG00000276155. [P10636-7]
DR   Ensembl; ENST00000620070; ENSP00000484491; ENSG00000277956. [P10636-8]
DR   Ensembl; ENST00000620818; ENSP00000484321; ENSG00000277956. [P10636-5]
DR   Ensembl; ENST00000620981; ENSP00000481769; ENSG00000276155. [P10636-5]
DR   Ensembl; ENST00000621329; ENSP00000477703; ENSG00000276155. [P10636-8]
DR   Ensembl; ENST00000622106; ENSP00000482244; ENSG00000277956. [P10636-6]
DR   Ensembl; ENST00000622728; ENSP00000479142; ENSG00000276155. [P10636-6]
DR   Ensembl; ENST00000626571; ENSP00000486039; ENSG00000276155. [P10636-6]
DR   Ensembl; ENST00000628393; ENSP00000487570; ENSG00000276155. [P10636-2]
DR   Ensembl; ENST00000631447; ENSP00000488373; ENSG00000277956. [P10636-5]
DR   Ensembl; ENST00000632500; ENSP00000487837; ENSG00000277956. [P10636-7]
DR   Ensembl; ENST00000633047; ENSP00000488245; ENSG00000277956. [P10636-2]
DR   Ensembl; ENST00000634049; ENSP00000487819; ENSG00000277956. [P10636-8]
DR   GeneID; 4137; -.
DR   KEGG; hsa:4137; -.
DR   UCSC; uc002ijr.4; human. [P10636-1]
DR   UCSC; uc002ijs.4; human. [P10636-8]
DR   UCSC; uc002ijt.4; human. [P10636-6]
DR   UCSC; uc002iju.4; human. [P10636-2]
DR   UCSC; uc002ijx.4; human. [P10636-7]
DR   UCSC; uc010dau.3; human. [P10636-9]
DR   UCSC; uc021tyv.1; human. [P10636-5]
DR   UCSC; uc021tyw.1; human. [P10636-4]
DR   CTD; 4137; -.
DR   GeneCards; MAPT; -.
DR   GeneReviews; MAPT; -.
DR   HGNC; HGNC:6893; MAPT.
DR   HPA; CAB000151; -.
DR   MIM; 157140; gene+phenotype.
DR   MIM; 172700; phenotype.
DR   MIM; 260540; phenotype.
DR   MIM; 600274; phenotype.
DR   MIM; 601104; phenotype.
DR   neXtProt; NX_P10636; -.
DR   Orphanet; 275864; Behavioral variant of frontotemporal dementia.
DR   Orphanet; 240071; Classical progressive supranuclear palsy.
DR   Orphanet; 100070; Progressive non-fluent aphasia.
DR   Orphanet; 240103; Progressive supranuclear palsy - corticobasal syndrome.
DR   Orphanet; 240085; Progressive supranuclear palsy - parkinsonism.
DR   Orphanet; 240112; Progressive supranuclear palsy - progressive non fluent aphasia.
DR   Orphanet; 240094; Progressive supranuclear palsy - pure akinesia with gait freezing.
DR   Orphanet; 100069; Semantic dementia.
DR   PharmGKB; PA238; -.
DR   eggNOG; NOG148882; -.
DR   GeneTree; ENSGT00530000063491; -.
DR   HOVERGEN; HBG000991; -.
DR   InParanoid; P10636; -.
DR   KO; K04380; -.
DR   OMA; CSEIETH; -.
DR   OrthoDB; EOG738045; -.
DR   TreeFam; TF316358; -.
DR   Reactome; R-HSA-264870; Caspase-mediated cleavage of cytoskeletal proteins.
DR   ChiTaRS; MAPT; human.
DR   EvolutionaryTrace; P10636; -.
DR   GeneWiki; Tau_protein; -.
DR   GenomeRNAi; 4137; -.
DR   NextBio; 16246; -.
DR   PMAP-CutDB; P10636; -.
DR   PRO; PR:P10636; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; P10636; -.
DR   ExpressionAtlas; P10636; baseline and differential.
DR   Genevisible; P10636; HS.
DR   GO; GO:0030424; C:axon; IDA:UniProtKB.
DR   GO; GO:0005930; C:axoneme; IEA:Ensembl.
DR   GO; GO:0044297; C:cell body; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0030426; C:growth cone; IDA:UniProtKB.
DR   GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW.
DR   GO; GO:0005875; C:microtubule associated complex; TAS:ProtInc.
DR   GO; GO:0097418; C:neurofibrillary tangle; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0034399; C:nuclear periphery; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0045298; C:tubulin complex; IDA:UniProtKB.
DR   GO; GO:0034185; F:apolipoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0071813; F:lipoprotein particle binding; IPI:UniProtKB.
DR   GO; GO:0008017; F:microtubule binding; IDA:UniProtKB.
DR   GO; GO:0017124; F:SH3 domain binding; IPI:UniProtKB.
DR   GO; GO:0005200; F:structural constituent of cytoskeleton; TAS:ProtInc.
DR   GO; GO:0007628; P:adult walking behavior; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; TAS:Reactome.
DR   GO; GO:0008088; P:axon cargo transport; IEA:Ensembl.
DR   GO; GO:0048675; P:axon extension; IEA:Ensembl.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0006921; P:cellular component disassembly involved in execution phase of apoptosis; TAS:Reactome.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0048699; P:generation of neurons; NAS:UniProtKB.
DR   GO; GO:0008631; P:intrinsic apoptotic signaling pathway in response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0047497; P:mitochondrion transport along microtubule; IEA:Ensembl.
DR   GO; GO:0032387; P:negative regulation of intracellular transport; IEA:Ensembl.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0045773; P:positive regulation of axon extension; IDA:UniProtKB.
DR   GO; GO:0031116; P:positive regulation of microtubule polymerization; IDA:UniProtKB.
DR   GO; GO:0012501; P:programmed cell death; TAS:Reactome.
DR   GO; GO:0010506; P:regulation of autophagy; IGI:MGI.
DR   GO; GO:0031113; P:regulation of microtubule polymerization; NAS:UniProtKB.
DR   GO; GO:0060632; P:regulation of microtubule-based movement; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0010033; P:response to organic substance; IEA:Ensembl.
DR   InterPro; IPR027324; MAP2/MAP4/Tau.
DR   InterPro; IPR001084; MAP_tubulin-bd_rpt.
DR   InterPro; IPR002955; Tau.
DR   PANTHER; PTHR11501; PTHR11501; 1.
DR   Pfam; PF00418; Tubulin-binding; 4.
DR   PRINTS; PR01261; TAUPROTEIN.
DR   PROSITE; PS00229; TAU_MAP_1; 4.
DR   PROSITE; PS51491; TAU_MAP_2; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Alzheimer disease;
KW   Cell membrane; Cell projection; Complete proteome; Cytoplasm;
KW   Cytoskeleton; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Glycation; Glycoprotein; Isopeptide bond; Membrane;
KW   Microtubule; Neurodegeneration; Parkinsonism; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:1512244}.
FT   CHAIN         2    758       Microtubule-associated protein tau.
FT                                /FTId=PRO_0000072739.
FT   REPEAT      561    591       Tau/MAP 1.
FT   REPEAT      592    622       Tau/MAP 2.
FT   REPEAT      623    653       Tau/MAP 3.
FT   REPEAT      654    685       Tau/MAP 4.
FT   SITE         24     24       Not glycated.
FT   SITE         44     44       Not glycated.
FT   SITE         67     67       Not glycated.
FT   SITE        381    381       Not glycated.
FT   SITE        391    391       Not glycated.
FT   SITE        392    392       Not glycated.
FT   SITE        394    394       Not glycated.
FT   SITE        465    465       Not glycated.
FT   SITE        497    497       Not glycated.
FT   SITE        507    507       Not glycated.
FT   SITE        541    541       Not glycated.
FT   SITE        557    557       Not glycated.
FT   SITE        571    571       Not glycated.
FT   SITE        574    574       Not glycated.
FT   SITE        584    584       Not glycated.
FT   SITE        591    591       Not glycated.
FT   SITE        607    607       Not glycated.
FT   SITE        611    611       Not glycated.
FT   SITE        615    615       Not glycated.
FT   SITE        628    628       Not glycated.
FT   SITE        634    634       Not glycated.
FT   SITE        638    638       Not glycated.
FT   SITE        648    648       Not glycated.
FT   SITE        657    657       Not glycated.
FT   SITE        660    660       Not glycated.
FT   SITE        687    687       Not glycated.
FT   SITE        692    692       Not glycated.
FT   SITE        700    700       Not glycated.
FT   SITE        702    702       Not glycated.
FT   SITE        712    712       Not glycated.
FT   SITE        755    755       Not glycated.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000269|PubMed:1512244}.
FT   MOD_RES      18     18       Phosphotyrosine; by FYN.
FT                                {ECO:0000269|PubMed:14999081}.
FT   MOD_RES      46     46       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P19332}.
FT   MOD_RES      61     61       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P19332}.
FT   MOD_RES      71     71       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P19332}.
FT   MOD_RES     214    214       Phosphoserine; by SGK1.
FT                                {ECO:0000269|PubMed:16982696}.
FT   MOD_RES     396    396       Phosphoserine; in PHF-tau.
FT                                {ECO:0000269|PubMed:1899488}.
FT   MOD_RES     470    470       Phosphothreonine; by PDPK1.
FT                                {ECO:0000269|PubMed:9614189}.
FT   MOD_RES     484    484       Deamidated asparagine; in tau and PHF-
FT                                tau; partial.
FT                                {ECO:0000269|PubMed:1512244}.
FT   MOD_RES     498    498       Phosphothreonine; by PDPK1.
FT                                {ECO:0000269|PubMed:15546861}.
FT   MOD_RES     514    514       Phosphotyrosine; by TTBK1.
FT                                {ECO:0000269|PubMed:16923168}.
FT   MOD_RES     515    515       Phosphoserine; by PDPK1 and TTBK1.
FT                                {ECO:0000269|PubMed:16923168}.
FT   MOD_RES     516    516       Phosphoserine; by PDPK1 and TTBK1.
FT                                {ECO:0000269|PubMed:15546861,
FT                                ECO:0000269|PubMed:16923168,
FT                                ECO:0000269|PubMed:19451179,
FT                                ECO:0000269|PubMed:9614189}.
FT   MOD_RES     519    519       Phosphoserine; by CK1, PDPK1 and TTBK1.
FT                                {ECO:0000269|PubMed:14761950,
FT                                ECO:0000269|PubMed:15546861,
FT                                ECO:0000269|PubMed:16923168,
FT                                ECO:0000269|PubMed:19451179,
FT                                ECO:0000269|PubMed:21327254,
FT                                ECO:0000269|PubMed:9614189}.
FT   MOD_RES     522    522       Phosphothreonine; by CK1 and PDPK1.
FT                                {ECO:0000269|PubMed:14761950,
FT                                ECO:0000269|PubMed:15546861,
FT                                ECO:0000269|PubMed:19451179}.
FT   MOD_RES     529    529       Phosphothreonine; by BRSK1, BRSK2, DYRK2
FT                                and PDPK1. {ECO:0000269|PubMed:15546861,
FT                                ECO:0000269|PubMed:18599021,
FT                                ECO:0000269|PubMed:19451179,
FT                                ECO:0000269|PubMed:21985311,
FT                                ECO:0000269|PubMed:9614189}.
FT   MOD_RES     531    531       Phosphoserine; by PKA.
FT                                {ECO:0000269|PubMed:15546861,
FT                                ECO:0000269|PubMed:16443603,
FT                                ECO:0000269|PubMed:19451179,
FT                                ECO:0000269|PubMed:9614189}.
FT   MOD_RES     534    534       Phosphothreonine; by PDPK1.
FT                                {ECO:0000269|PubMed:16443603,
FT                                ECO:0000269|PubMed:19451179}.
FT   MOD_RES     548    548       Phosphothreonine; by GSK3-beta and PDPK1.
FT                                {ECO:0000269|PubMed:14690523,
FT                                ECO:0000269|PubMed:15546861,
FT                                ECO:0000269|PubMed:16443603}.
FT   MOD_RES     552    552       Phosphoserine; by PDPK1.
FT                                {ECO:0000269|PubMed:15546861,
FT                                ECO:0000269|PubMed:16443603,
FT                                ECO:0000269|PubMed:9614189}.
FT   MOD_RES     554    554       Phosphoserine; by PHK.
FT                                {ECO:0000269|PubMed:16443603,
FT                                ECO:0000269|PubMed:8999860}.
FT   MOD_RES     579    579       Phosphoserine; by MARK1, BRSK1, BRSK2 and
FT                                PHK. {ECO:0000269|PubMed:15546861,
FT                                ECO:0000269|PubMed:16443603,
FT                                ECO:0000269|PubMed:19451179,
FT                                ECO:0000269|PubMed:21985311,
FT                                ECO:0000269|PubMed:7706316,
FT                                ECO:0000269|PubMed:8999860,
FT                                ECO:0000269|PubMed:9614189}.
FT   MOD_RES     596    596       Deamidated asparagine; in tau and PHF-
FT                                tau; partial.
FT   MOD_RES     602    602       Phosphoserine; by PHK.
FT                                {ECO:0000269|PubMed:8999860}.
FT   MOD_RES     606    606       Phosphoserine; by PHK.
FT                                {ECO:0000269|PubMed:8999860}.
FT   MOD_RES     610    610       Phosphoserine; by MARK1; in PHF-tau.
FT                                {ECO:0000269|PubMed:7706316}.
FT   MOD_RES     622    622       Phosphoserine; by MARK1; in PHF-tau.
FT                                {ECO:0000269|PubMed:7706316}.
FT   MOD_RES     641    641       Phosphoserine; by MARK1; in PHF-tau.
FT                                {ECO:0000269|PubMed:7706316}.
FT   MOD_RES     669    669       Phosphoserine; by PHK.
FT                                {ECO:0000269|PubMed:8999860}.
FT   MOD_RES     673    673       Phosphoserine; by MARK1; in PHF-tau.
FT                                {ECO:0000269|PubMed:7706316}.
FT   MOD_RES     711    711       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P10637}.
FT   MOD_RES     713    713       Phosphoserine; by CK1 and PDPK1.
FT                                {ECO:0000269|PubMed:14761950,
FT                                ECO:0000269|PubMed:15546861,
FT                                ECO:0000269|PubMed:16443603,
FT                                ECO:0000269|PubMed:19451179,
FT                                ECO:0000269|PubMed:21327254,
FT                                ECO:0000269|PubMed:9614189}.
FT   MOD_RES     717    717       Phosphoserine; alternate.
FT                                {ECO:0000269|PubMed:21327254}.
FT   MOD_RES     720    720       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P10637}.
FT   MOD_RES     721    721       Phosphoserine; by CK1 and PDPK1.
FT                                {ECO:0000269|PubMed:14761950,
FT                                ECO:0000269|PubMed:15546861,
FT                                ECO:0000269|PubMed:19451179,
FT                                ECO:0000269|PubMed:21327254,
FT                                ECO:0000269|PubMed:9614189}.
FT   MOD_RES     726    726       Phosphoserine.
FT                                {ECO:0000269|PubMed:15546861}.
FT   MOD_RES     733    733       Phosphoserine; by CaMK2 and TTBK1.
FT                                {ECO:0000269|PubMed:16923168}.
FT   MOD_RES     739    739       Phosphoserine; by PDPK1 and TTBK1.
FT                                {ECO:0000269|PubMed:16443603,
FT                                ECO:0000269|PubMed:16923168,
FT                                ECO:0000269|PubMed:19451179,
FT                                ECO:0000269|PubMed:9614189}.
FT   MOD_RES     744    744       Phosphothreonine; by TTBK1.
FT                                {ECO:0000269|PubMed:16923168}.
FT   CARBOHYD     87     87       N-linked (Glc) (glycation); in PHF-tau;
FT                                in vitro. {ECO:0000269|PubMed:19451179}.
FT   CARBOHYD    383    383       N-linked (Glc) (glycation); in PHF-tau;
FT                                in vitro. {ECO:0000269|PubMed:19451179}.
FT   CARBOHYD    467    467       N-linked (Glc) (glycation); in PHF-tau;
FT                                in vitro. {ECO:0000269|PubMed:19451179}.
FT   CARBOHYD    480    480       N-linked (Glc) (glycation); in PHF-tau;
FT                                in vitro. {ECO:0000269|PubMed:19451179}.
FT   CARBOHYD    491    491       N-linked (Glc) (glycation); in PHF-tau;
FT                                in vitro. {ECO:0000269|PubMed:19451179}.
FT   CARBOHYD    525    525       O-linked (GlcNAc).
FT                                {ECO:0000269|PubMed:21327254}.
FT   CARBOHYD    542    542       N-linked (Glc) (glycation); in PHF-tau;
FT                                in vitro. {ECO:0000269|PubMed:19451179}.
FT   CARBOHYD    551    551       N-linked (Glc) (glycation); in PHF-tau;
FT                                in vitro. {ECO:0000269|PubMed:19451179}.
FT   CARBOHYD    555    555       O-linked (GlcNAc).
FT                                {ECO:0000269|PubMed:21327254}.
FT   CARBOHYD    576    576       N-linked (Glc) (glycation); in PHF-tau;
FT                                in vitro. {ECO:0000269|PubMed:19451179}.
FT   CARBOHYD    597    597       N-linked (Glc) (glycation); in PHF-tau;
FT                                in vitro. {ECO:0000269|PubMed:19451179}.
FT   CARBOHYD    598    598       N-linked (Glc) (glycation); in PHF-tau;
FT                                in vitro. {ECO:0000269|PubMed:19451179}.
FT   CARBOHYD    664    664       N-linked (Glc) (glycation); in PHF-tau;
FT                                in vitro. {ECO:0000269|PubMed:19451179}.
FT   CARBOHYD    670    670       N-linked (Glc) (glycation); in PHF-tau;
FT                                in vitro. {ECO:0000269|PubMed:19451179}.
FT   CARBOHYD    686    686       N-linked (Glc) (glycation); in PHF-tau;
FT                                in vitro. {ECO:0000269|PubMed:19451179}.
FT   CARBOHYD    717    717       O-linked (GlcNAc); alternate.
FT                                {ECO:0000269|PubMed:21327254}.
FT   DISULFID    608    639       {ECO:0000250}.
FT   CROSSLNK    571    571       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin); in
FT                                PHF-tau. {ECO:0000269|PubMed:16443603}.
FT   CROSSLNK    628    628       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin); in
FT                                PHF-tau. {ECO:0000269|PubMed:16443603}.
FT   CROSSLNK    670    670       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin); in
FT                                PHF-tau. {ECO:0000269|PubMed:16443603}.
FT   VAR_SEQ       1     44       MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDA
FT                                GLK -> MLRALQQRKR (in isoform Tau-A).
FT                                {ECO:0000303|PubMed:2516729}.
FT                                /FTId=VSP_003175.
FT   VAR_SEQ      45     73       Missing (in isoform Tau-A, isoform Tau-D
FT                                and isoform Fetal-tau).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:2498079,
FT                                ECO:0000303|PubMed:2516729,
FT                                ECO:0000303|PubMed:3131773,
FT                                ECO:0000303|Ref.7}.
FT                                /FTId=VSP_003176.
FT   VAR_SEQ      74    102       Missing (in isoform Tau-A, isoform Tau-B,
FT                                isoform Tau-D, isoform Tau-E and isoform
FT                                Fetal-tau). {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:2484340,
FT                                ECO:0000303|PubMed:2498079,
FT                                ECO:0000303|PubMed:2516729,
FT                                ECO:0000303|PubMed:3131773,
FT                                ECO:0000303|Ref.6, ECO:0000303|Ref.7}.
FT                                /FTId=VSP_003177.
FT   VAR_SEQ     103    104       Missing (in isoform Tau-A).
FT                                {ECO:0000303|PubMed:2516729}.
FT                                /FTId=VSP_003178.
FT   VAR_SEQ     125    375       Missing (in isoform Tau-A, isoform Tau-B,
FT                                isoform Tau-C, isoform Tau-D, isoform
FT                                Tau-E, isoform Tau-F and isoform Fetal-
FT                                tau). {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:2484340,
FT                                ECO:0000303|PubMed:2498079,
FT                                ECO:0000303|PubMed:2516729,
FT                                ECO:0000303|PubMed:3131773,
FT                                ECO:0000303|Ref.6, ECO:0000303|Ref.7}.
FT                                /FTId=VSP_003179.
FT   VAR_SEQ     395    460       Missing (in isoform Tau-A, isoform Tau-B,
FT                                isoform Tau-C, isoform Tau-D, isoform
FT                                Tau-E, isoform Tau-F and isoform Fetal-
FT                                tau). {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:2484340,
FT                                ECO:0000303|PubMed:2498079,
FT                                ECO:0000303|PubMed:2516729,
FT                                ECO:0000303|PubMed:3131773,
FT                                ECO:0000303|Ref.6, ECO:0000303|Ref.7}.
FT                                /FTId=VSP_003180.
FT   VAR_SEQ     502    502       S -> SATKQVQRRPPPAGPRSER (in isoform Tau-
FT                                G). {ECO:0000305}.
FT                                /FTId=VSP_026780.
FT   VAR_SEQ     592    622       Missing (in isoform Tau-A, isoform Tau-B,
FT                                isoform Tau-C and isoform Fetal-tau).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:2484340,
FT                                ECO:0000303|PubMed:2516729,
FT                                ECO:0000303|PubMed:3131773,
FT                                ECO:0000303|Ref.7}.
FT                                /FTId=VSP_003181.
FT   VARIANT       5      5       R -> H (in FTD; reduces the ability of
FT                                tau to promote microtubule assembly and
FT                                promotes fibril formation in vitro;
FT                                dbSNP:rs63750959).
FT                                {ECO:0000269|PubMed:11921059}.
FT                                /FTId=VAR_019660.
FT   VARIANT       5      5       R -> L (in PSNP1; delays assembly
FT                                initiation and lowers the mass of
FT                                microtubules formed; but the assembly
FT                                rate is increased compared to normal tau;
FT                                dbSNP:rs63750959).
FT                                {ECO:0000269|PubMed:12325083}.
FT                                /FTId=VAR_019661.
FT   VARIANT      17     17       T -> M (in dbSNP:rs144611688).
FT                                {ECO:0000269|PubMed:20020531}.
FT                                /FTId=VAR_064622.
FT   VARIANT      30     30       T -> A. {ECO:0000269|PubMed:20020531}.
FT                                /FTId=VAR_064623.
FT   VARIANT     285    285       D -> N (risk factor for PSNP1;
FT                                dbSNP:rs62063786).
FT                                {ECO:0000269|PubMed:10534245,
FT                                ECO:0000269|PubMed:9629852}.
FT                                /FTId=VAR_010340.
FT   VARIANT     289    289       V -> A (risk factor for PSNP1;
FT                                dbSNP:rs62063787).
FT                                {ECO:0000269|PubMed:10534245,
FT                                ECO:0000269|PubMed:9629852}.
FT                                /FTId=VAR_010341.
FT   VARIANT     370    370       R -> W (in dbSNP:rs17651549).
FT                                /FTId=VAR_056121.
FT   VARIANT     441    441       Y -> H (in dbSNP:rs2258689).
FT                                {ECO:0000269|PubMed:1420178,
FT                                ECO:0000269|PubMed:15365985,
FT                                ECO:0000269|PubMed:9629852}.
FT                                /FTId=VAR_010342.
FT   VARIANT     447    447       S -> P (in dbSNP:rs10445337).
FT                                {ECO:0000269|PubMed:9629852}.
FT                                /FTId=VAR_010343.
FT   VARIANT     574    574       K -> T (in PIDB; reduces the ability to
FT                                promote microtubule assembly by 70%).
FT                                {ECO:0000269|PubMed:11089577,
FT                                ECO:0000269|PubMed:11117542}.
FT                                /FTId=VAR_010344.
FT   VARIANT     583    583       L -> V (in FTD; less able to promote
FT                                microtubule assembly than wild-type tau).
FT                                {ECO:0000269|PubMed:12509859}.
FT                                /FTId=VAR_019662.
FT   VARIANT     589    589       G -> V (in FTD).
FT                                {ECO:0000269|PubMed:9641683,
FT                                ECO:0000269|PubMed:9973279}.
FT                                /FTId=VAR_010345.
FT   VARIANT     596    596       N -> K (in FTD; with parkinsonism).
FT                                {ECO:0000269|PubMed:10412802,
FT                                ECO:0000269|PubMed:10489057,
FT                                ECO:0000269|PubMed:10802785,
FT                                ECO:0000269|PubMed:12473774,
FT                                ECO:0000269|PubMed:9789048}.
FT                                /FTId=VAR_010346.
FT   VARIANT     597    597       Missing (in FTD).
FT                                {ECO:0000269|PubMed:9973279}.
FT                                /FTId=VAR_010347.
FT   VARIANT     613    613       N -> H (in FTD; reduced the ability of
FT                                tau to promote microtubule assembly
FT                                without having a significant effect on
FT                                tau filament formation; effects at both
FT                                the RNA and the protein level).
FT                                {ECO:0000269|PubMed:11585254,
FT                                ECO:0000269|PubMed:11906000}.
FT                                /FTId=VAR_019663.
FT   VARIANT     613    613       Missing (in PSNP1/atypical PSNP1;
FT                                heterozygosity may be a risk factor for
FT                                both a PSNP1-like syndrome and Parkinson
FT                                disease; reduced the ability of tau to
FT                                promote microtubule assembly without
FT                                having a significant effect on tau
FT                                filament formation; effects at both the
FT                                RNA and the protein level).
FT                                {ECO:0000269|PubMed:11220749,
FT                                ECO:0000269|PubMed:11906000,
FT                                ECO:0000269|PubMed:14991828,
FT                                ECO:0000269|PubMed:14991829}.
FT                                /FTId=VAR_019664.
FT   VARIANT     617    617       V -> I (in dbSNP:rs116733906).
FT                                {ECO:0000269|PubMed:20020531}.
FT                                /FTId=VAR_064624.
FT   VARIANT     618    618       P -> L (in FTD; most common mutation;
FT                                reduction in the ability to promote
FT                                microtubule assembly; accelerates
FT                                aggregation of tau into filaments).
FT                                {ECO:0000269|PubMed:10214944,
FT                                ECO:0000269|PubMed:9641683,
FT                                ECO:0000269|PubMed:9736786,
FT                                ECO:0000269|PubMed:9789048,
FT                                ECO:0000269|PubMed:9973279}.
FT                                /FTId=VAR_010348.
FT   VARIANT     618    618       P -> S (in FTD and CBD; reduction in the
FT                                ability to promote microtubule assembly).
FT                                {ECO:0000269|PubMed:10374757,
FT                                ECO:0000269|PubMed:10553987,
FT                                ECO:0000269|PubMed:11071507,
FT                                ECO:0000269|PubMed:16240366}.
FT                                /FTId=VAR_010349.
FT   VARIANT     620    620       G -> V (in PSNP1).
FT                                {ECO:0000269|PubMed:16157753}.
FT                                /FTId=VAR_037439.
FT   VARIANT     622    622       S -> N (in FTD; minimal parkinsonism;
FT                                very early age of onset).
FT                                {ECO:0000269|PubMed:10208578}.
FT                                /FTId=VAR_010350.
FT   VARIANT     634    634       K -> M (in FTD).
FT                                {ECO:0000269|PubMed:15883319}.
FT                                /FTId=VAR_037440.
FT   VARIANT     637    637       S -> F (in PIDB; markedly reduced ability
FT                                of tau to promote microtubule assembly).
FT                                {ECO:0000269|PubMed:11891833}.
FT                                /FTId=VAR_019665.
FT   VARIANT     654    654       V -> M (in FTD; ultrastructural and
FT                                biochemical characteristics
FT                                indistinguishable from Alzheimer disease;
FT                                accelerates aggregation of tau into
FT                                filaments). {ECO:0000269|PubMed:10214944,
FT                                ECO:0000269|PubMed:9629852}.
FT                                /FTId=VAR_010351.
FT   VARIANT     659    659       E -> V (in FTD).
FT                                {ECO:0000269|PubMed:11117541}.
FT                                /FTId=VAR_019666.
FT   VARIANT     669    669       S -> L (in fatal respiratory
FT                                hypoventilation; unusual apparent
FT                                autosomal recessive inheritance; reduced
FT                                binding to microtubules as well as
FT                                increased fibrillization and
FT                                aggregation).
FT                                {ECO:0000269|PubMed:14595660}.
FT                                /FTId=VAR_019667.
FT   VARIANT     686    686       K -> I (in PIDB; 90% reduction in the
FT                                rate of microtubule assembly).
FT                                {ECO:0000269|PubMed:11601501}.
FT                                /FTId=VAR_019668.
FT   VARIANT     706    706       G -> R (in PIDB; in vitro the mutation
FT                                reduces the ability of tau to promote
FT                                microtubule assembly by 25 to 30%).
FT                                {ECO:0000269|PubMed:10604746,
FT                                ECO:0000269|PubMed:11117542}.
FT                                /FTId=VAR_010352.
FT   VARIANT     723    723       R -> W (in FTD/Alzheimer disease;
FT                                accelerates aggregation of tau into
FT                                filaments; reduces tau phosphorylation in
FT                                cells compared to both the wild-type and
FT                                other mutant forms).
FT                                {ECO:0000269|PubMed:10214944,
FT                                ECO:0000269|PubMed:11278002,
FT                                ECO:0000269|PubMed:11889249,
FT                                ECO:0000269|PubMed:14517953,
FT                                ECO:0000269|PubMed:9641683,
FT                                ECO:0000269|PubMed:9973279}.
FT                                /FTId=VAR_010353.
FT   MUTAGEN     515    515       S->E: No association with plasma
FT                                membrane.
FT   MUTAGEN     516    516       S->E: No association with plasma
FT                                membrane.
FT   MUTAGEN     519    519       S->E: No association with plasma
FT                                membrane.
FT   MUTAGEN     531    531       S->A: No decrease in microtubule-binding
FT                                and nucleation activity after in vitro
FT                                phosphorylation of mutant protein.
FT   MUTAGEN     548    548       T->A: 50% Decrease in microtubule-binding
FT                                after in vitro phosphorylation of mutant
FT                                protein.
FT   MUTAGEN     548    548       T->E: No association with plasma
FT                                membrane.
FT   MUTAGEN     552    552       S->A: 70% decrease in microtubule-binding
FT                                after in vitro phosphorylation of mutant
FT                                protein.
FT   MUTAGEN     552    552       S->E: No association with plasma
FT                                membrane.
FT   MUTAGEN     579    579       S->A: 8% decrease in microtubule-binding
FT                                after in vitro phosphorylation of mutant
FT                                protein.
FT   MUTAGEN     713    713       S->E: No association with plasma
FT                                membrane.
FT   MUTAGEN     721    721       S->E: No association with plasma
FT                                membrane.
FT   MUTAGEN     726    726       S->E: No association with plasma
FT                                membrane.
FT   MUTAGEN     730    730       S->E: No association with plasma
FT                                membrane.
FT   MUTAGEN     739    739       S->E: No association with plasma
FT                                membrane.
FT   CONFLICT     48     48       L -> P (in Ref. 6; AAU45390).
FT                                {ECO:0000305}.
FT   CONFLICT    414    414       H -> L (in Ref. 5; AAC04277).
FT                                {ECO:0000305}.
FT   CONFLICT    557    557       K -> M (in Ref. 12; AAS17881).
FT                                {ECO:0000305}.
FT   CONFLICT    591    591       K -> S (in Ref. 12; AAS17881).
FT                                {ECO:0000305}.
FT   CONFLICT    617    617       V -> Q (in Ref. 17; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    622    622       S -> K (in Ref. 17; AA sequence).
FT                                {ECO:0000305}.
FT   STRAND      625    627       {ECO:0000244|PDB:4E0N}.
SQ   SEQUENCE   758 AA;  78928 MW;  D46C66CDBCD196E8 CRC64;
     MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDGSEEPG
     SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTEIPEG TTAEEAGIGD TPSLEDEAAG
     HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG
     GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA
     QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKGQDAPLE
     FTFHVEITPN VQKEQAHSEE HLGRAAFPGA PGEGPEARGP SLGEDTKEAD LPEPSEKQPA
     AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKNRPCL SPKHPTPGSS
     DPLIQPSSPA VCPEPPSSPK YVSSVTSRTG SSGAKEMKLK GADGKTKIAT PRGAAPPGQK
     GQANATRIPA KTPPAPKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRSRTP SLPTPPTREP
     KKVAVVRTPP KSPSSAKSRL QTAPVPMPDL KNVKSKIGST ENLKHQPGGG KVQIINKKLD
     LSNVQSKCGS KDNIKHVPGG GSVQIVYKPV DLSKVTSKCG SLGNIHHKPG GGQVEVKSEK
     LDFKDRVQSK IGSLDNITHV PGGGNKKIET HKLTFRENAK AKTDHGAEIV YKSPVVSGDT
     SPRHLSNVSS TGSIDMVDSP QLATLADEVS ASLAKQGL
//
